Tim Stratford is Chairman at AmCham China and Managing Partner in Covington & Burling LLP’s Beijing office and a member of the International Trade, Corporate and Government Affairs Practice Groups. Mr. Stratford’s practice is focused on advising international clients doing business in China and assisting Chinese companies seeking to expand their businesses globally. As a former Assistant U.S. Trade Representative, Mr. Stratford is the most senior former U.S. trade official working as a member of the U.S. business community in China. Except for the five years he spent in Washington, D.C. in government service (2005-2010), Mr. Stratford has lived and worked continuously in the greater China region since 1982.

While at USTR, Mr. Stratford was responsible for developing and implementing U.S. trade policy toward mainland China, Taiwan, Hong Kong, Macao and Mongolia. He worked closely with other senior U.S. and Chinese officials from numerous government departments and agencies to address problems encountered by companies engaged in bilateral trade and investment and co-chaired a number of important bilateral working groups and dialogues established under the U.S.-China Joint Commission on Commerce and Trade and the U.S.-China Strategic & Economic Dialogue.

Prior to serving at USTR, Mr. Stratford was General Counsel for General Motors’ China operations, where he was a member of GM’s senior management team in China and oversaw the company’s legal and trade policy work. Mr. Stratford also served previously as Minister-Counselor for Commercial Affairs at the U.S. Embassy in Beijing and as Chairman of the American Chamber of Commerce in China. He is a graduate of Harvard Law School and Brigham Young University, and is fluent in Mandarin and Cantonese.

Alan Beebe was appointed President of the American Chamber of Commerce in China on Mar. 14, 2016.

Alan was an Executive Director based in Beijing, leading EY China’s Cleantech and Supply Chain and Operations (SC&O) practices. His clients include major global corporations, primarily diversified industrials and high-technology companies operating in China.

Prior to joining EY, Alan held Executive positions with the China Greentech Initiative (CGTI), IBM, and management consulting firms AT Kearney and PRTM. He has twenty years of management consulting experience in the US, China and other Asian countries helping clients develop and implement sound business, operations and technology strategies. At EY China, he helps global clients transform their business models to drive new revenue opportunities and preserve profitability in China’s changing economic climate.

From 2010 to 2013, Alan was a Managing Director with CGTI, a collaboration platform serving over 50 international energy and environmental companies. At CGTI, he led advisory services and strategic research across all major areas of energy and cleantech. In 2014, CGTI merged with the Paulson Institute, founded by Hank Paulson.

Alan holds a Master’s degree from Yale University in International Relations and a Bachelor’s degree in Business Administration and Computer Science from the University of Nebraska-Lincoln in the United States. He is a Board of Advisor of the Yale Club of Beijing and in that capacity promotes academic and cultural exchanges between the United States and China. Alan has lived in China since 2002 and speaks Chinese fluently.

徐旸女士现任陶氏化学大中华区政府事务总经理，负责政府和政策事务。此前，她分别在渣打银行和杜邦公司主管政府事务工作，在法规和标准制定，项目投资，知识产权保护等领域有多年经验。

2000年初至2001年底，徐旸女士任阿里巴巴集团中国区公共关系部经理，在早期帮助创立了这个中国知名互联网品牌，参与策划并组织了如“西湖论剑”等在行业内有重要影响的活动。

1993年至2000年，徐旸女士任职于《中国日报》社国内新闻部，负责共青团中央、中央外事、台港澳、全国人大、中国人民解放军有关新闻的报道工作，后担任报社“中央组”的协调人，曾随中国国家领导人出访过20多个国家与地区。任职期间，徐旸女士曾获得 “全国优秀共青团员”、“中直机关优秀青年岗位能手”等荣誉称号和近十个国家级新闻奖项。

徐旸女士1993年毕业于南京大学外国语学院，获学士学位。

As Chair of AmCham China Policy Committee and Insurance Forum, Les Ross is a longstanding leader of the American business and legal communities in China and in frequent contact with government officials and other stakeholders.

Mr. Ross concentrates his practice on mergers and acquisitions and regulatory matters and has experience in a broad range of industries. He has represented both foreign and local companies and has particular experience advising foreign companies on competition law and regulatory compliance in China.

Mr. Ross represents foreign companies in their strategic expansion in China through direct investments and mergers and acquisitions in industries ranging alphabetically from agriculture to water services. He also has extensive experience representing foreign banks and corporations, including Chinese entities, in their strategic expansion in the United States, particularly focusing on M&A and regulatory clearances and compliance. He has also represented clients in trade, dispute resolution and regulatory matters in China.

Roberta Lipson is CEO and founder of United Family Healthcare (UFH). She has over 30 years of experience as a pioneer in the healthcare industry in China. She originally co-founded United Family Healthcare’s predecessor company Chindex in 1981, expanding the business from China’s top medical equipment distribution company into China’s first and largest foreign-invested healthcare system. After almost two decades, UFH has established itself with hospitals and clinics in Beijing, Shanghai, Guangzhou, Wuxi, Tianjin, Qingdao, and Nanjing as the provider of choice for those seeking premium, personalized healthcare. United Family Healthcare was rated in 2016 as “The Most Trusted Healthcare Brand of China” by the Chinese Business Journal.

Ms.Lipson is an active leader in the business community in Beijing, having served as a director of the U.S. China Business Council, as well as 4 successive terms on the Board of tGovernors of the American Chamber of Commerce in China (AmCham), and as Co-Chair of the AmCham Healthcare Forum. She also chairs the Board of the United Foundation for China’s Health (UFCH), and is a co- founder of Beijing’s Jewish Community, Kehillat Beijing. Because of her outstanding contribution in China, Roberta Lipson received “The Great Wall Friendship Reward”, the highest honor that Beijing government gives to foreign experts in Beijing. In 2014 Roberta was honored by AMCHAM as the inaugural recipient of the China Pioneer Award. She was named as a “Top 10 Business Leader of China” by Sina.com in 2015, and earlier she led the company to win the U.S. State Department ACE Award for Corporate Excellence. Ms. Lipson holds a BA from Brandeis University and an MBA from Columbia University.

李碧菁女士是和睦家医疗总裁，创始人。她有着超过30年在中国医疗健康领域的丰富经验。李碧菁女士1981年创建美中互利公司，主营业务从销售大型医疗设备逐渐扩展到医疗卫生服务业。李碧菁女士是中国第一家外资私立医疗的创始人，在中国开创了“和睦家”这一拥有国际医疗服务、管理模式和服务理念的医疗品牌。经过20年的发展，和睦家医疗在北京、上海、天津、广州、青岛、无锡等地设有医院和诊所，为民众提供高质量的医疗服务。2016年，和睦家医疗被中国经营报评为“最值得信赖医疗品牌”。

李碧菁女士积极活跃在北京的各种商业社团，担任着众多职位，如美中贸易全国委员会董事，连续四届任中国美国商会董事，中国美国商会医疗论坛联合主席等；同时李碧菁女士还担任着和睦家中国医疗基金会主席，并联合创立了北京赐乐业－犹太人社团。由于她的突出贡献，2009年李碧菁女士获得“长城友谊奖”，该奖项是北京市政府授予在北京工作的外国专家的最高奖项。2015年，李碧菁女士获选新浪“十大经济人物”。李碧菁女士拥有美国哥伦比亚大学工商管理硕士学位和BRANDEIS大学历史学学士学位。

Ying has over 17 years of pharmaceutical industry experience spanning across commercial, development and manufacturing. As Worldwide Business Development Lead for Asia, Ying is responsible for accelerating mid-to-long-term revenue and profitability growth in China and Japan by developing strategy, and identifying, analyzing, and prioritizing organic and inorganic business opportunities, as well as executing new initiatives and partnerships to drive growth for Pfizer Asia. The functions she oversees include strategy, business development, and commercial development.

Ying leads the Asia Business Development with her rich and diversified experience and capabilities gained from local and global markets. In the past 2.5 years, she has been based in China as the Strategy & Business Development Lead, and Chief of Staff for the Greater China Region. Before that, Ying worked in the Pfizer US Headquarters for 12 years. Back in New York she was the Global Lead for Commercial Decision Analytics, BAI between 2014 and 2016, managing a global best-in-class-talent team that provides advanced analytics-based business insight, such as forecast, promotional sensitivity (ROI), digital, and field force analytics, to Pfizer’s business units across the regions. Prior to that, she was Sr. Director and Asia Lead with Pfizer Consulting & Execution (PCE). In that role she created the internal consulting team in Asia to support business transformations and strategy executions for commercial leaders. During her 5 years with PCE she also led multiple development projects, including the China Post Approval Commitment project, and the Quality Risk Management and Quality Performance Reporting for clinical development. Before the PCE role she worked in PGS as a Six Sigma Lead and also in WRD as a statistician. Ying started her career with Abbott Labs in an internal consulting group.

Ying holds a Ph.D. in Industrial Engineering & Management Sciences from Northwestern University, and a Bachelor’s degree in Chemistry from Fudan University in Shanghai.

Xu Sitao is Chief Economist and Partner of Deloitte China, spearheading Deloitte's economic and industry research. Prior to Deloitte, he was Chief Representative of China and EIU forecasting director at the Economist Group from 2004 to 2014.

Sitao worked for MMS International of Standard and Poor’s Group in Singapore as the Economist for Indonesia, Korea and Thailand in 1995. He joined Standard Chartered Bank as Regional Treasury Economist in 1996. From 2000 to 2002, he was Societe Generale’s Chief Economist for Asia. In 2003, he became the Head of Economics of ICBC (Asia).

Sitao has written for YaleGlobal Online, the Asian Wall Street Journal, Financial Times, Caijing, Caixin and 21st Century Business Herald. He appears regularly on CNBC, Bloomberg, CCTV, and other TV shows as a commentator on China. He is on the Speaker Retainer Program for the Virginia-based CFA Institute, and is often invited by leading MNCs to their board rooms, to present key issues on China.

Sitao holds a B.A. in Economics from Peking University, a M.A. in Economics from the University of Connecticut, and a M.S. in Finance from Boston College. He was a visiting scholar at Hoover Institution at Stanford University in 2012. He is also a guest professor at the School of Economics and Management of Tsinghua University.

李恺先生是德勤风险管理咨询团队的合伙人，市场风险、资本市场解决方案咨询服务负责人。在金融市场产品开发、风险管理和交易台管理方面拥有超过16年的工作经验。曾长期服务于纽约华尔街投行巴克莱资本和花旗银行金融市场部（Citi Capital Markets）从事固定收益和信用衍生品交易台的交易管理、产品定价、风险管理工作。李恺先生多次被政府、企业和大专院校邀请就金融产品估值和互联网金融专题提供培训和交流。
李恺先生具备特许金融分析师认证（CFA），金融风险管理师（FRM）资质，是CFA认证3级考试阅卷人。李恺先生本科和硕士均毕业于纽约哥伦比亚大学，为哥伦比亚大学北京校友会会长，校友代表委员会委员，协助中国北方区本科招生推荐工作。